These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 23474327)
1. Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: candidacy for systemic treatment or clinical trials. Memon K; Kulik L; Lewandowski RJ; Gupta R; Ryu RK; Miller FH; Vouche M; Atassi R; Ganger D; Mulcahy MF; Salem R J Vasc Interv Radiol; 2013 Aug; 24(8):1189-1197.e2. PubMed ID: 23474327 [TBL] [Abstract][Full Text] [Related]
2. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Salem R; Gordon AC; Mouli S; Hickey R; Kallini J; Gabr A; Mulcahy MF; Baker T; Abecassis M; Miller FH; Yaghmai V; Sato K; Desai K; Thornburg B; Benson AB; Rademaker A; Ganger D; Kulik L; Lewandowski RJ Gastroenterology; 2016 Dec; 151(6):1155-1163.e2. PubMed ID: 27575820 [TBL] [Abstract][Full Text] [Related]
3. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA Trials; 2012 Aug; 13():144. PubMed ID: 22913492 [TBL] [Abstract][Full Text] [Related]
5. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Salem R; Lewandowski RJ; Kulik L; Wang E; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Ibrahim SM; Senthilnathan S; Baker T; Gates VL; Atassi B; Newman S; Memon K; Chen R; Vogelzang RL; Nemcek AA; Resnick SA; Chrisman HB; Carr J; Omary RA; Abecassis M; Benson AB; Mulcahy MF Gastroenterology; 2011 Feb; 140(2):497-507.e2. PubMed ID: 21044630 [TBL] [Abstract][Full Text] [Related]
6. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma. Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686 [TBL] [Abstract][Full Text] [Related]
7. Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization. Memon K; Kulik LM; Lewandowski RJ; Wang E; Wang J; Ryu RK; Hickey R; Vouche M; Baker T; Ganger D; Gates VL; Habib A; Mulcahy MF; Salem R J Vasc Interv Radiol; 2014 Jul; 25(7):1056-66. PubMed ID: 24613269 [TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Locoregional Treatment during Immunotherapy with Nivolumab for Hepatocellular Carcinoma: A Retrospective Study of 41 Interventions in 29 Patients. Marinelli B; Cedillo M; Pasik SD; Charles D; Murthy S; Patel RS; Fischman A; Ranade M; Bishay V; Nowakowski S; Sung M; Marron T; Lookstein R; Schwartz M; Kim E J Vasc Interv Radiol; 2020 Nov; 31(11):1729-1738.e1. PubMed ID: 33012649 [TBL] [Abstract][Full Text] [Related]
9. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience. Tohme S; Sukato D; Chen HW; Amesur N; Zajko AB; Humar A; Geller DA; Marsh JW; Tsung A J Vasc Interv Radiol; 2013 Nov; 24(11):1632-8. PubMed ID: 24160821 [TBL] [Abstract][Full Text] [Related]
10. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. Memon K; Kulik L; Lewandowski RJ; Mulcahy MF; Benson AB; Ganger D; Riaz A; Gupta R; Vouche M; Gates VL; Miller FH; Omary RA; Salem R J Hepatol; 2013 Jan; 58(1):73-80. PubMed ID: 23000237 [TBL] [Abstract][Full Text] [Related]
11. Treatment of hepatocellular carcinoma with radioembolization: gathering assumptions for trial design. Reig M; Burrel M; Bruix J J Vasc Interv Radiol; 2013 Aug; 24(8):1197-9. PubMed ID: 23885915 [No Abstract] [Full Text] [Related]
12. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. Lance C; McLennan G; Obuchowski N; Cheah G; Levitin A; Sands M; Spain J; Srinivas S; Shrikanthan S; Aucejo FN; Kim R; Menon KV J Vasc Interv Radiol; 2011 Dec; 22(12):1697-705. PubMed ID: 21983055 [TBL] [Abstract][Full Text] [Related]
13. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study. Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450 [TBL] [Abstract][Full Text] [Related]
14. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma. Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S; J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371 [TBL] [Abstract][Full Text] [Related]
16. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis. Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644 [TBL] [Abstract][Full Text] [Related]
17. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Memon K; Kulik L; Lewandowski RJ; Wang E; Riaz A; Ryu RK; Sato KT; Marshall K; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Senthilnathan S; Baker T; Gates VL; Abecassis M; Benson AB; Mulcahy MF; Omary RA; Salem R Gastroenterology; 2011 Aug; 141(2):526-35, 535.e1-2. PubMed ID: 21664356 [TBL] [Abstract][Full Text] [Related]
18. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. Kooby DA; Egnatashvili V; Srinivasan S; Chamsuddin A; Delman KA; Kauh J; Staley CA; Kim HS J Vasc Interv Radiol; 2010 Feb; 21(2):224-30. PubMed ID: 20022765 [TBL] [Abstract][Full Text] [Related]